Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 15 clinical trials
Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL

ENKTL is a highly aggressive NHL with a higher incidence in Asia. L-asparaginase containing chemotherapy regimens are the standard first-line treatment with apparently toxicities. In 2020 ASH

  • 0 views
  • 06 May, 2022
  • 1 location
A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.

non-metastatic invasive breast carcinoma, high-grade soft tissue sarcoma, osteosarcoma, Ewing's sarcoma, acute myeloid leukemia, Hodgkin's or aggressive non-Hodgkin's lymphoma. Four assessment visits

  • 0 views
  • 16 Feb, 2021
  • 1 location
Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

This study will evaluate the efficacy of Pixantrone with rituximab, ifosfamide and etoposide as measured by the overall metabolic response rate after 2 cycles of treatment or at permanent treatment discontinuation.

  • 7 views
  • 27 Feb, 2022
  • 15 locations
Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy

A phase II prospective, non-randomized study. The study aim is to evaluate the feasibility and activity of high-dose therapy with stem cell in elderly patients with aggressive lymphoma relapsed FIT or resistant to first line therapy.

aggressive non-hodgkin's lymphoma
ifosfamide
etoposide
neutrophil count
rituximab
  • 44 views
  • 22 Jan, 2021
  • 15 locations
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

TC-110 T cells in patients with aggressive NHL (DLBCL, PMBCL, TFL), high-risk indolent NHL (including MCL), or adult ALL.

lymphoid leukemia
adult acute lymphocytic leukemia
hodgkin's disease
lymphocytic leukemia
diffuse large b-cell lymphoma
  • 10 views
  • 02 Mar, 2022
  • 2 locations
A Study Of The Selective PKC-β Inhibitor MS- 553

A Phase I/II Dose-Escalation and Expansion Study Of The Selective PKC-Β Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

venetoclax
chronic lymphocytic leukemia
lymphoid leukemia
obinutuzumab
rituximab
  • 14 views
  • 13 Jun, 2022
  • 5 locations
Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

This phase I trial studies the best dose and side effects of paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel)/rituximab-coated nanoparticle AR160 in treating patients with B-cell non-Hodgkin lymphoma that has come back or is not responding to treatment. Nab-paclitaxel/rituximab-coated nanoparticle AR160 is a combination of paclitaxel albumin-stabilized nanoparticle formulation and rituximab. Drugs …

absolute neutrophil count
nab-paclitaxel/rituximab-coated nanoparticle ar160
lymphoid leukemia
paclitaxel albumin-stabilized nanoparticle formulation
neutrophil count
  • 1 views
  • 04 Oct, 2022
  • 1 location
Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

This phase II trial studies how well pembrolizumab and external beam radiation therapy work in treating patients with non-Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may …

aggressive non-hodgkin's lymphoma
pembrolizumab
glomerular filtration rate
neutrophil count
follicular lymphoma
  • 8 views
  • 29 May, 2021
  • 2 locations
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute lymphoblastic leukemia (B-ALL)

venetoclax
indolent lymphoma
b-cell small lymphocytic lymphoma
monoclonal antibodies
leukemia
  • 0 views
  • 24 Mar, 2022
  • 6 locations
A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination with Ublituximab in Subjects with B-Cell Lymphoma or Chronic Lymphocytic Leukemia

measurable disease
monoclonal antibodies
lymphocytic leukemia
b-cell lymphoma
chronic lymphocytic leukemia
  • 0 views
  • 17 Oct, 2022
  • 5 locations